{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:06:49Z","timestamp":1789520809020,"version":"build-2803163510"},"reference-count":151,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbcan.2026.189688","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:07:45Z","timestamp":1787008065000},"page":"189688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel immunotherapeutic strategies for colorectal cancer treatment: Advances, challenges, and future directions"],"prefix":"10.1016","volume":"1881","author":[{"given":"Engeng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoyang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangfa","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bbcan.2026.189688_bb0005","article-title":"Colorectal cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-023-00488-4","article-title":"Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics","volume":"8","author":"Valdeolivas","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189688_bb0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc.2016.126","article-title":"Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer","volume":"17","author":"Dienstmann","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189688_bb0020","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189688_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1353787","article-title":"Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy","volume":"15","author":"Nicolini","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","article-title":"Recent developments in immunotherapy for gastrointestinal tract cancers","volume":"17","author":"Chong","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189688_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1440830","article-title":"The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies","volume":"15","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189688_bb0045","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4_suppl","key":"10.1016\/j.bbcan.2026.189688_bb0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2017.35.4_suppl.519","article-title":"Nivolumab in patients with DNA mismatch repair deficient\/microsatellite instability high metastatic colorectal cancer: update from CheckMate 142","volume":"35","author":"Overman","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"8094","key":"10.1016\/j.bbcan.2026.189688_bb0055","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41586-025-09679-4","article-title":"Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers","volume":"648","author":"Tan","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-024-01634-6","article-title":"Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition","volume":"18","author":"Glaviano","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189688_bb0065","article-title":"Tumor-infiltrating lymphocytes in colorectal Cancer: the fundamental indication and application on immunotherapy","volume":"12","author":"Bai","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189688_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41556-025-01862-z","article-title":"Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose\u2013mesenchymal transformation","author":"Wang","year":"2026","journal-title":"Nat. Cell Biol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189688_bb0080","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189688_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188447","article-title":"Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: from bench to bedside","volume":"1874","author":"Lizardo","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2026.189688_bb0090","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2016.34.15_suppl.3501","article-title":"Nivolumab \u00b1 ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): checkmate-142 interim results","volume":"34","author":"Overman","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189688_bb0095","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1634\/theoncologist.2019-0129","article-title":"Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer","volume":"24","author":"Morse","year":"2019","journal-title":"Oncologist"},{"issue":"21","key":"10.1016\/j.bbcan.2026.189688_bb0100","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189688_bb0105","doi-asserted-by":"crossref","first-page":"S1217","DOI":"10.1016\/j.annonc.2024.08.2263","article-title":"LBA24 neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2","volume":"35","author":"Chalabi","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189688_bb0110","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.1016\/j.annonc.2024.08.572","article-title":"503O neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: results of the NICHE-3 study","volume":"35","author":"de Gooyer","year":"2024","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189688_bb0115","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"de Gooyer","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-med-080222-100847","article-title":"Application and expectations for immune checkpoint blockade of LAG3 and TIGIT","volume":"76","author":"Dumbrava","year":"2025","journal-title":"Annu. Rev. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.bbcan.2026.189688_bb0125","first-page":"A507","article-title":"477\u00a0COM902 (anti-TIGIT antibody) monotherapy \u2013 preliminary evaluation of safety, tolerability, pharmacokinetics and receptor occupancy in patients with advanced solid tumors (NCT04354246)","volume":"9","author":"Dumbrava","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189688_bb0130","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00262-021-02921-8","article-title":"COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade","volume":"70","author":"Hansen","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189688_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100639","article-title":"A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer","volume":"7","author":"Garralda","year":"2022","journal-title":"ESMO Open"},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2026.189688_bb0140","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2021.39.15_suppl.3584","article-title":"A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer","volume":"39","author":"Garralda","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6545","key":"10.1016\/j.bbcan.2026.189688_bb0145","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.abg1209","article-title":"Bispecific antibodies","volume":"372","author":"Brinkmann","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189688_bb0150","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jconrel.2023.05.032","article-title":"Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review","volume":"359","author":"Beishenaliev","year":"2023","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189688_bb0155","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189688_bb0160","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbcan.2026.189688_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2026.1758251","article-title":"Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps","volume":"16","author":"Shao","year":"2026","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0170","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189688_bb0175","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-024-01956-6","article-title":"Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison","volume":"23","author":"Cheng","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189688_bb0190","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"29","key":"10.1016\/j.bbcan.2026.189688_bb0195","doi-asserted-by":"crossref","first-page":"11272","DOI":"10.1039\/D4SC00851K","article-title":"Macrophage-engaging peptidic bispecific antibodies (pBsAbs) for immunotherapy via a facile bioconjugation strategy","volume":"15","author":"Shao","year":"2024","journal-title":"Chem. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0200","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s42003-021-01790-2","article-title":"Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity","volume":"4","author":"Mandrup","year":"2021","journal-title":"Commun. Biol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189688_bb0205","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s10555-024-10213-7","article-title":"CAR T cells in solid tumors and metastasis: paving the way forward","volume":"43","author":"Sirini","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbcan.2026.189688_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.904137","article-title":"Recent advances in CAR-T cells therapy for colorectal cancer","volume":"13","author":"Qin","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008275","article-title":"Cars are sharpening their weapons","volume":"12","author":"Pievani","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","article-title":"Current advances and challenges in CAR T-cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment","volume":"12","author":"Yan","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0225","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-024-02047-2","article-title":"Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond","volume":"23","author":"Zhou","year":"2024","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189688_bb0230","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment","volume":"18","author":"Liu","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189688_bb0235","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.11.015","article-title":"Clinical advances of mRNA vaccines for cancer immunotherapy","volume":"6","author":"Yaremenko","year":"2025","journal-title":"Med"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189688_bb0245","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189688_bb0250","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3390\/vaccines11101599","article-title":"Advances in mRNA-based cancer vaccines","volume":"11","author":"Ni","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189688_bb0255","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0260","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","article-title":"Nanomaterials for cancer therapy: current progress and perspectives","volume":"14","author":"Cheng","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189688_bb0265","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.apsb.2021.03.033","article-title":"Influencing factors and strategies of enhancing nanoparticles into tumors in vivo","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189688_bb0270","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s13346-022-01241-3","article-title":"Nanocarriers for cancer nano-immunotherapy","volume":"13","author":"Rana","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0275","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41378-024-00743-z","article-title":"Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy","volume":"10","author":"Gholami","year":"2024","journal-title":"Microsyst. Nanoeng."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0280","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-024-01628-4","article-title":"Personalized nanovaccines for treating solid cancer metastases","volume":"17","author":"Feng","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189688_bb0615","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189688_bb0420","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann. Oncol."},{"issue":"25","key":"10.1016\/j.bbcan.2026.189688_bb0285","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal Cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189688_bb0290","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrclinonc.2009.237","article-title":"Microsatellite instability in colorectal cancer-the stable evidence","volume":"7","author":"Vilar","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.bbcan.2026.189688_bb0295","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1200\/JCO.23.00702","article-title":"Pembrolizumab in patients with tumors with high tumor mutational burden: results from the targeted agent and profiling utilization registry study","volume":"41","author":"Duvivier","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189688_bb0300","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/annonc\/mdz134","article-title":"Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer","volume":"30","author":"Schrock","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189688_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103374","article-title":"TMB or not TMB as a biomarker: that is the question","volume":"163","author":"Addeo","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189688_bb0310","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid Tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189688_bb0315","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMc2031965","article-title":"The Spectrum of benefit from checkpoint blockade in hypermutated Tumors","volume":"384","author":"Rousseau","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189688_bb0320","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189688_bb0325","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"issue":"7793","key":"10.1016\/j.bbcan.2026.189688_bb0330","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189688_bb0335","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","article-title":"Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple Cancer types","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189688_bb0340","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"issue":"7693","key":"10.1016\/j.bbcan.2026.189688_bb0345","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.bbcan.2026.189688_bb0350","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"issue":"10207","key":"10.1016\/j.bbcan.2026.189688_bb0355","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.bbcan.2026.189688_bb0360","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.21.02615","article-title":"Using circulating tumor DNA in colorectal cancer: current and evolving practices","volume":"40","author":"Malla","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189688_bb0365","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189688_bb0370","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/1078-0432.CCR-18-1851","article-title":"The immunoscore: colon cancer and beyond","volume":"26","author":"Angell","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"6411","key":"10.1016\/j.bbcan.2026.189688_bb0375","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189688_bb0380","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.cell.2020.07.005","article-title":"Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front","volume":"182","author":"Schurch","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0385","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat. Med."},{"issue":"6477","key":"10.1016\/j.bbcan.2026.189688_bb0390","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.bbcan.2026.189688_bb0395","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189688_bb0400","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189688_bb0405","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0410","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189688_bb0415","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"28","key":"10.1016\/j.bbcan.2026.189688_bb0425","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.23.02261","article-title":"Randomized phase II trial of immunotherapy-based Total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)","volume":"42","author":"Xia","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0430","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12916-025-04087-x","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study","volume":"23","author":"Lin","year":"2025","journal-title":"BMC Med."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189688_bb0435","first-page":"1124","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0440","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0445","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189688_bb0450","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189688_bb0455","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189688_bb0460","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12272-023-01452-3","article-title":"Beyond DNA sensing: expanding the role of cGAS\/STING in immunity and diseases","volume":"46","author":"Seok","year":"2023","journal-title":"Arch. Pharm. Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189688_bb0465","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.semradonc.2019.12.009","article-title":"Type I interferon response in radiation-induced anti-tumor immunity","volume":"30","author":"Zhang","year":"2020","journal-title":"Semin. Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189688_bb0470","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic Tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0475","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The cytosolic DNA-sensing cGAS-STING pathway in cancer","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189688_bb0480","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189688_bb0485","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189688_bb0490","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fonc.2019.00156","article-title":"Novel approaches to improve the efficacy of Immuno-radiotherapy","volume":"9","author":"Shevtsov","year":"2019","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189688_bb0495","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1158\/1078-0432.CCR-20-4632","article-title":"A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation for patients with metastatic colorectal cancer","volume":"27","author":"Monjazeb","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189688_bb0500","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/s41416-023-02392-x","article-title":"Advancing translational research for colorectal immuno-oncology","volume":"129","author":"Thomas","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189688_bb0505","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7693","key":"10.1016\/j.bbcan.2026.189688_bb0510","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189688_bb0515","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/2159-8290.CD-24-1033","article-title":"Vascular normalization augments the antitumor efficacy of combined HDAC inhibitor with immunotherapy in solid Tumors","volume":"15","author":"Wang","year":"2025","journal-title":"Cancer Discov."},{"issue":"7649","key":"10.1016\/j.bbcan.2026.189688_bb0520","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"issue":"7693","key":"10.1016\/j.bbcan.2026.189688_bb0525","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.bbcan.2026.189688_bb0530","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189688_bb0535","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","article-title":"Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial","volume":"7","author":"Martinelli","year":"2021","journal-title":"JAMA Oncol."},{"issue":"6371","key":"10.1016\/j.bbcan.2026.189688_bb0540","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6510","key":"10.1016\/j.bbcan.2026.189688_bb0545","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"issue":"6536","key":"10.1016\/j.bbcan.2026.189688_bb0550","doi-asserted-by":"crossref","first-page":"eabc4552","DOI":"10.1126\/science.abc4552","article-title":"The microbiome and human cancer","volume":"371","author":"Sepich-Poore","year":"2021","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189688_bb0555","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","article-title":"Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma","volume":"28","author":"Lee","year":"2022","journal-title":"Nat. Med."},{"issue":"6529","key":"10.1016\/j.bbcan.2026.189688_bb0560","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189688_bb0565","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.cell.2023.03.011","article-title":"Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment","volume":"186","author":"Bender","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0570","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1038\/s41467-021-24331-1","article-title":"Microbial short-chain fatty acids modulate CD8(+) T cell responses and improve adoptive immunotherapy for cancer","volume":"12","author":"Luu","year":"2021","journal-title":"Nat. Commun."},{"issue":"6575","key":"10.1016\/j.bbcan.2026.189688_bb0575","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bbcan.2026.189688_bb0580","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189688_bb0585","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.cell.2024.04.015","article-title":"Circadian tumor infiltration and function of CD8(+) T cells dictate immunotherapy efficacy","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"7946","key":"10.1016\/j.bbcan.2026.189688_bb0590","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-022-05605-0","article-title":"Dendritic cells direct circadian anti-tumour immune responses","volume":"614","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189688_bb0595","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2023.01.007","article-title":"Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer","volume":"182","author":"Rousseau","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2026.189688_bb0600","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S1470-2045(21)00546-5","article-title":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","volume":"22","author":"Qian","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0605","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010424","article-title":"Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors","volume":"13","author":"Taieb","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189688_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114336","article-title":"Duration of immunotherapy in dMMR\/MSI-H metastatic colorectal cancer patients","volume":"212","author":"Margalit","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189688_bb0620","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","article-title":"ctDNA-based molecular residual disease and survival in resectable colorectal cancer","volume":"30","author":"Nakamura","year":"2024","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189688_bb0625","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with Cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189688_bb0640","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0645","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12865-024-00599-y","article-title":"Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors","volume":"25","author":"Wang","year":"2024","journal-title":"BMC Immunol."},{"key":"10.1016\/j.bbcan.2026.189688_bb0650","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1157805","article-title":"Endocrine side effects of immune checkpoint inhibitors","volume":"14","author":"Cardona","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"7","key":"10.1016\/j.bbcan.2026.189688_bb0655","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0660","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/imr.13239","article-title":"Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: current understanding and future directions","volume":"318","author":"Dougan","year":"2023","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189688_bb0630","doi-asserted-by":"crossref","first-page":"ITC17","DOI":"10.7326\/AITC202402200","article-title":"Immune-related adverse events of immune checkpoint inhibitors","volume":"177","author":"Ramos-Casals","year":"2024","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0635","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.13262","article-title":"Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189688_bb0670","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamadermatol.2023.3003","article-title":"Cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment: a systematic review and meta-analysis","volume":"159","author":"Du","year":"2023","journal-title":"JAMA Dermatol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189688_bb0675","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189688_bb0680","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fimmu.2020.02023","article-title":"Predictive biomarkers of immune checkpoint inhibitors-related toxicities","volume":"11","author":"Xu","year":"2020","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189688_bb0685","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189688_bb0665","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"36","key":"10.1016\/j.bbcan.2026.189688_bb0690","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2026.189688_bb0695","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189688_bb0700","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.bbcan.2026.189688_bb0705","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.bbcan.2026.189688_bb0710","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189688_bb0715","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","article-title":"Clinical relevance of tumour-associated macrophages","volume":"19","author":"Pittet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189688_bb0720","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189688_bb0725","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial","volume":"28","author":"Sartore-Bianchi","year":"2022","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.bbcan.2026.189688_bb0730","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1158\/1078-0432.CCR-23-0079","article-title":"Circulating tumor DNA to drive treatment in metastatic colorectal cancer","volume":"29","author":"Patelli","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189688_bb0735","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189688_bb0740","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189688_bb0745","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0750","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189688_bb0755","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:19:52Z","timestamp":1789517992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":151,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0304419X26001605"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189688","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel immunotherapeutic strategies for colorectal cancer treatment: Advances, challenges, and future directions","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189688"}}